<?xml version="1.0" encoding="UTF-8"?>
<p>The International Diabetes Federation states that type-2 diabetes is a chronic condition that occurs when there are raised levels of plasma glucose, attributed to insufficient/lack production of insulin, or because the body cannot use the insulin it produces (
 <xref rid="B72" ref-type="bibr">International Diabetes Federation, 2019</xref>). It is estimated that around 463 million people live with diagnosed diabetes, and this number is expected to rise to 700 million by 2045. The first line of treatment of diabetes is a combination of exercise, changes in lifestyle, dietary modification, and drug prescription; sulfonylureas and meglitinides, metformin, PPAR antagonists (like thiazolidinediones), α-glucosidase inhibitors, among others (
 <xref rid="B47" ref-type="bibr">Defronzo et al., 2015</xref>). However, people from low- and middle-income countries have restricted access to pharmaceutical treatment due to economic restraints; thus, they sometimes use alone or in combination different medicinal plants to treat hyperglycemia, diabetes and some of its complications (
 <xref rid="B195" ref-type="bibr">World Health Organization, 1999</xref>; 
 <xref rid="B107" ref-type="bibr">Mata et al., 2013</xref>). Studies regarding the potential antidiabetic properties of 
 <italic>Terminalia</italic> sp. have been consistent from the last 10 years (according to the Web of Science and Scopus databases); however, it is important to mention that most of these reports represent only 
 <italic>in vitro</italic> studies. This section aims to gather recent studies with 
 <italic>Terminalia</italic> sp. and their potential antidiabetic activity.
</p>
